The Molbio Diagnostics IPO GMP has attracted attention ahead of the company’s stock market debut. Molbio Diagnostics, a point-of-care molecular diagnostics company, is launching its mainboard IPO with a price band of ₹768 to ₹807 per share. The IPO opened for subscription on August 10, 2026, and will close on August 12, 2026. The total issue size is approximately ₹939.70 crore.
As of the latest available reports, the grey market premium is around ₹130 per share, although GMP is unofficial and can change frequently. At this level, the implied grey market price would be around ₹937, based on the upper price band of ₹807. However, investors should not treat GMP as a guaranteed listing price.
Molbio Diagnostics is known for its Truenat molecular diagnostics platform and operates in the point-of-care diagnostics segment. The company has also filed its IPO documents with SEBI, with the proposed offering originally structured around a fresh issue and an offer for sale.
Molbio Diagnostics IPO GMP Today
The latest reported Molbio Diagnostics IPO GMP is around ₹130 per share. This figure reflects activity in the unofficial grey market and should be viewed only as an indication of market sentiment.
Based on the upper IPO price of ₹807, a GMP of ₹130 would imply an estimated grey market price of approximately ₹937.
| Particulars | Details |
| IPO Price Band | ₹768–₹807 |
| Latest GMP | Around ₹130 |
| Upper Price Band | ₹807 |
| Indicative GMP Price | ₹937 |
| Indicative Premium | Around 16.1% |
| IPO Status | Open |
| IPO Opening Date | August 10, 2026 |
| IPO Closing Date | August 12, 2026 |
Molbio Diagnostics GMP Trend
The grey market premium can change from one day to another depending on demand, broader market conditions and investor sentiment.
Recent reports have shown varying GMP levels before the IPO opened. Therefore, readers checking the Molbio Diagnostics IPO GMP today should always consider the latest available figure rather than relying on an older update.
The IPO opened on August 10 with the price band fixed at ₹768–₹807
Molbio Diagnostics IPO Details
Molbio Diagnostics is offering shares through a combination of a fresh issue and an offer for sale. The IPO is expected to raise approximately ₹939.70 crore.
| IPO Detail | Information |
| Company | Molbio Diagnostics Limited |
| IPO Type | Mainboard IPO |
| IPO Opening Date | August 10, 2026 |
| IPO Closing Date | August 12, 2026 |
| Price Band | ₹768–₹807 per share |
| Issue Size | Approximately ₹939.70 crore |
| Fresh Issue | Approximately ₹200 crore |
| Offer for Sale | Approximately ₹739.70 crore |
| Face Value | ₹1 per share |
| Lot Size | 18 shares |
| Listing | NSE and BSE |
| Sector | Molecular Diagnostics |
| DRHP Draft | View DRHP |
About Molbio Diagnostics
Molbio Diagnostics is a healthcare technology company focused on point-of-care molecular diagnostics. Its flagship Truenat platform is designed to enable molecular testing closer to the point of patient care.
The company was founded in 2000 and is headquartered in Goa. Its products are used across healthcare settings, including government health programmes, diagnostic laboratories and hospitals. Molbio has also developed an international presence.
The company says its Truenat platform is central to its molecular diagnostics business. Its IPO filing was submitted to SEBI in 2025.
Molbio Diagnostics Financial Performance
Molbio Diagnostics has reported growth in revenue and profitability in recent financial years.
| Financial Metric | FY25 | FY26 |
| Total Income | ₹1,020 crore | ₹1,455.17 crore |
| Profit After Tax | ₹138.5 crore | ₹164.14 crore |
Molbio Diagnostics IPO GMP vs Estimated Listing Price
The relationship between GMP and estimated listing price is straightforward.
| Calculation | Amount |
| Upper IPO Price | ₹807 |
| GMP Used for Illustration | ₹130 |
| Indicative Price | ₹937 |
| Indicative Premium | ₹130 |
| Premium Percentage | ~16.1% |
Should You Rely on Molbio Diagnostics IPO GMP?
No single indicator should be used to evaluate an IPO.
GMP can provide a snapshot of unofficial market sentiment, but it does not measure a company’s long-term business performance. It also does not guarantee listing gains.
For a more complete assessment, readers should look at:
- Revenue and profit growth
- Valuation at the IPO price
- Business model
- Customer and product concentration
- Debt and cash flows
- Use of IPO proceeds
- Competitive environment
- Risks disclosed in the offer document
Conclusion
The Molbio Diagnostics IPO GMP indicates positive unofficial market sentiment, with recent reports placing the GMP around ₹130 per share. Against the upper IPO price of ₹807, this points to an indicative grey market price of about ₹937
.However, GMP should not be considered a substitute for fundamental analysis. Molbio Diagnostics operates in an interesting point-of-care molecular diagnostics segment and has reported growth in revenue and profitability. At the same time, investors should carefully evaluate valuation, customer concentration, product concentration and the large OFS component.
The IPO is open from August 10 to August 12, 2026, with a price band of ₹768–₹807 per share and an issue size of approximately ₹939.70 crore.
Molbio Diagnostics IPO GMP FAQs
The latest reported GMP is around ₹130 per share. GMP is unofficial and can change frequently, so the latest market update should always be checked before publishing or relying on the figure.
The IPO price band has been fixed at ₹768 to ₹807 per share.
The IPO opened on August 10, 2026, and is scheduled to close on August 12, 2026.
Using a GMP of ₹130 and the upper issue price of ₹807, the indicative grey market price would be approximately ₹937 per share. This is only an estimate based on unofficial GMP and is not a guaranteed listing price.
No. GMP is an unofficial indicator of grey market sentiment. The actual listing price is determined by market trading on the stock exchanges and may differ substantially from the GMP-based estimate.